Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases

Patients with an epidermal growth factor receptor (EGFR) mutation are usually administered EGFR‐tyrosine kinase inhibitors (TKIs) as standard‐of‐care treatment. However, acquired resistance occurs between 9 and 13 months. The T790M‐resistant mutations are the most common, and osimertinib has been fo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Respirol Case Rep
Autors principals: Takeda, Takayuki, Itano, Hideki, Takeuchi, Mayumi, Nishimi, Yurika, Saitoh, Masahiko, Takeda, Sorou
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Ltd 2017
Matèries:
Case Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412970/
https://ncbi.nlm.nih.gov/pubmed/28469919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.241
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars